Maplelane Capital’s AstraZeneca AZN Stock Holding History

Maplelane Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-40,000	Closed	-$2.55M	–	94
2015 Q2	$2.55M	Sell	40,000 -23,000	-37%	-$1.57M	0.09%	105
2015 Q1	$4.31M	Sell	63,000 -7,000	-10%	-$486K	0.14%	122
2014 Q4	$4.93M	Buy	+70,000	New	+$5.01M	0.19%	95

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Maplelane Capital's AZN Position: Q3 2015 in Review

Maplelane Capital sold out of AstraZeneca (AZN) in Q3 2015, closing a stake of 40,000 shares — an estimated $2.55M sold.

Maplelane Capital first reported a position in AZN in Q4 2014 and held it in 3 quarters. The position peaked at $4.93M in Q4 2014. 371 funds tracked by Wall St. Rank hold AZN as of Q3 2015.

Maplelane Capital reported no remaining AstraZeneca position as of Q3 2015 after selling out during the quarter.
Maplelane Capital sold 40,000 AstraZeneca shares in Q3 2015, an estimated $2.55M.
Maplelane Capital first reported a position in AstraZeneca in Q4 2014 and held it in 3 quarters.
Maplelane Capital's AstraZeneca position peaked at $4.93M in Q4 2014.
371 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2015.

Based on Maplelane Capital's 13F filing for Q3 2015, filed 16 Nov 2015.